Leap Therapeutics Inc. (LPTX)
0.39
-0.01 (-1.27%)
At close: Apr 24, 2025, 3:56 PM
0.39
-1.53%
After-hours: Apr 24, 2025, 07:17 PM EDT
-1.27% (1D)
| Bid | 0.36 |
| Market Cap | 16.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -67.56M |
| EPS (ttm) | -1.81 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | -0.56 |
| Analyst | Hold |
| Ask | 0.4 |
| Volume | 476,889 |
| Avg. Volume (20D) | 2,578,750 |
| Open | 0.40 |
| Previous Close | 0.40 |
| Day's Range | 0.38 - 0.40 |
| 52-Week Range | 0.22 - 4.79 |
| Beta | 0.21 |
About LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and com...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 25, 2017
Employees 52
Stock Exchange NASDAQ
Ticker Symbol LPTX
Website https://www.leaptx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for LPTX stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 1935.62% from the latest price.
Stock Forecasts1 month ago
+16.88%
Leap Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
2 months ago
-12.06%
Leap Therapeutics shares are trading lower after HC Wainwright & Co downgraded the stock from Buy to Neutral.
